Compare peptides and GLP-1 medications
Choose a pair to compare approval, dose, results and side effects.
Each comparison states whether a trial tested the two options directly. Results from separate trials stay separate.
Compare medications
Brand names, approved uses and dose schedules.
Wegovy vs Zepbound
Compare approved uses, dose schedules and devices for the two products.
Direct trial: SURMOUNT-5
Mounjaro vs Ozempic
Mounjaro and Ozempic are different drugs used to lower blood sugar in adults with type 2 diabetes. A 40-week trial compared three tirzepatide doses with semaglutide 1 mg.
Direct trial: SURPASS-2
Wegovy vs Ozempic
Wegovy and Ozempic contain semaglutide, but their approved uses and dose schedules differ. The table compares their weekly injections and notes the separate tablet forms.
No direct trial
Mounjaro vs Zepbound
Mounjaro and Zepbound contain tirzepatide and share injection devices and dose-increase steps. Their approved uses, age limits and maintenance-dose guidance differ.
No direct trial
Zepbound vs Ozempic
Zepbound and Ozempic are different drugs, approved for different things. Zepbound treats weight and sleep apnea. Ozempic treats type 2 diabetes. No trial has compared these two products.
No direct trial
Wegovy vs Mounjaro
Wegovy and Mounjaro contain different drugs. Wegovy has a weight-management use; Mounjaro treats type 2 diabetes. Both also have heart-risk uses, with different patient groups covered.
No direct trial
Foundayo vs Zepbound
Foundayo is a daily orforglipron tablet. Zepbound is a weekly tirzepatide injection. Both labels cover weight management in adults, but their schedules and dosage forms differ.
No direct trial
Compare ingredients
Compounds, published studies and the limits of the evidence.
Tirzepatide vs semaglutide
See the SURMOUNT-5 results, the doses studied and the trial’s limits.
Direct trial: SURMOUNT-5
Retatrutide vs tirzepatide
Compare approval status, studied doses and reported side effects. Results from separate trials stay separate.
No direct trial
Survodutide vs tirzepatide
Compare approval status, studied doses and reported side effects. Results from separate trials stay separate.
No direct trial
Tesamorelin vs sermorelin
Both act at the same pituitary receptor. Tesamorelin has an approved use in adults with HIV; sermorelin’s Geref approvals ended in 2009.
No direct trial
Tesamorelin vs CJC-1295
Tesamorelin has approved daily doses. CJC-1295’s short human studies concern the long-acting form, not the molecule called CJC-1295 without DAC.
No direct trial
Compare forms
Daily routines and practical differences.
Comparisons at a glance
- Total comparisons
- 13
- With a direct trial
- 3
- Without a direct trial
- 10
What makes a fair comparison?
Explore the individual options
Find more detail on individual medicines, doses and side effects.